Spyre Therapeutics推出Spy772项目,启动化脓性汗腺炎SkyLight二期临床试验

美股速递
Aug 10

Spyre Therapeutics(股票代码:SYRE)正式宣布,其全新研发项目Spy772已启动,并同步开启针对化脓性汗腺炎(Hidradenitis Suppurativa)的SkyLight二期临床试验。这一消息标志着公司在炎症性疾病治疗领域迈出关键一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10